TN2017000003A1 - Misoprostol dispersible tablet. - Google Patents

Misoprostol dispersible tablet.

Info

Publication number
TN2017000003A1
TN2017000003A1 TN2017000003A TN2017000003A TN2017000003A1 TN 2017000003 A1 TN2017000003 A1 TN 2017000003A1 TN 2017000003 A TN2017000003 A TN 2017000003A TN 2017000003 A TN2017000003 A TN 2017000003A TN 2017000003 A1 TN2017000003 A1 TN 2017000003A1
Authority
TN
Tunisia
Prior art keywords
misoprostol
dispersible tablet
pharmaceutically acceptable
relates
preventionand
Prior art date
Application number
TN2017000003A
Other languages
English (en)
Inventor
Malaiarasan Arunachalam
Baskar Elumalai
Sekar Selvaraj
Prabhakaran Venugopal
Original Assignee
Azanta Danmark As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP14176821.8A external-priority patent/EP2965750B1/en
Priority claimed from US14/329,023 external-priority patent/US20160008310A1/en
Application filed by Azanta Danmark As filed Critical Azanta Danmark As
Publication of TN2017000003A1 publication Critical patent/TN2017000003A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TN2017000003A 2014-07-11 2015-07-10 Misoprostol dispersible tablet. TN2017000003A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176821.8A EP2965750B1 (en) 2014-07-11 2014-07-11 Misoprostol dispersible tablet
US14/329,023 US20160008310A1 (en) 2014-07-11 2014-07-11 Misoprostol dispersible tablet
PCT/DK2015/050216 WO2016004960A2 (en) 2014-07-11 2015-07-10 Misoprostol dispersible tablet

Publications (1)

Publication Number Publication Date
TN2017000003A1 true TN2017000003A1 (en) 2018-07-04

Family

ID=53879283

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2017000003A TN2017000003A1 (en) 2014-07-11 2015-07-10 Misoprostol dispersible tablet.

Country Status (15)

Country Link
US (2) US11406615B2 (enExample)
EP (1) EP3166597B1 (enExample)
JP (2) JP6532529B2 (enExample)
AU (1) AU2015287186B2 (enExample)
BR (1) BR112017000529A2 (enExample)
CA (1) CA2954086C (enExample)
DK (1) DK3166597T3 (enExample)
EA (1) EA039069B1 (enExample)
FI (1) FI3166597T3 (enExample)
MX (1) MX392771B (enExample)
NZ (1) NZ727876A (enExample)
PL (1) PL3166597T3 (enExample)
RU (1) RU2017104233A (enExample)
TN (1) TN2017000003A1 (enExample)
WO (1) WO2016004960A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108434110B (zh) * 2018-04-28 2019-09-10 浙江仙琚制药股份有限公司 米索前列醇组合物、片剂及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB994518A (en) 1962-07-18 1965-06-10 Needle Industries Ltd Improvements relating to shavers
US4301146A (en) * 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
US4335097A (en) 1981-01-15 1982-06-15 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Stabilized, prostaglandin-containing tablets with controlled rate of solubility, for local use and process for the preparation thereof
JPH06199779A (ja) 1992-06-08 1994-07-19 Newpharma Internatl Corp トランス−▲δ２▼−１５−デオキシ−１６−ヒドロキシ−１６−メチル−ｐｇ▲ｅ１▼のメチルエステル（ｂ−４０７）
EP0574185B1 (en) 1992-06-08 1997-09-03 Newpharma International Corporation PGE1 analogs
GB9419566D0 (en) * 1994-09-27 1994-11-16 El Refaey Hazem Oral prostagladins for the routine management of the third stage of labour
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6228213B1 (en) 1997-09-19 2001-05-08 University Of Nebraska-Lincoln Production of microcrystalline cellulose by reactive extrusion
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6526980B1 (en) 1999-08-26 2003-03-04 West Virginia University Cervical drug delivery system
KR20020062323A (ko) * 1999-12-06 2002-07-25 펜웨스트 파머슈티칼즈 컴파니 제약학적 초붕해제
GB2375303A (en) 2001-05-11 2002-11-13 Medical Res Council Method of inducing cervical ripening
GB0204771D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
SI21221A (sl) 2002-06-21 2003-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Hitro razpadljive tablete
TW200502000A (en) * 2003-03-28 2005-01-16 Kyowa Hakko Kogyo Kk Dividing tablet
WO2006125450A1 (en) 2005-05-26 2006-11-30 Atef Mohammed Mostafa Darwish Rectal and vaginal suppositories containing misoprostol
WO2006133048A2 (en) 2005-06-03 2006-12-14 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
EP1906937B1 (en) * 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
US7799530B2 (en) 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
WO2007035954A2 (en) 2005-09-23 2007-03-29 Duramed Pharmaceuticals, Inc. Vaginal tablets comprising misoprostol and methods of making and using the same
CN1939308A (zh) 2005-09-28 2007-04-04 应圣俊 一种米索前列醇栓剂
EP1987820A1 (en) 2007-05-04 2008-11-05 Christian Fiala, Ph. D. Slow release misoprostol for obstetric and/or gynaecological applications
EP2572705B1 (en) * 2007-10-01 2017-09-13 Laboratorios Lesvi, S.L. Orodispersible tablets
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
WO2010036878A1 (en) 2008-09-26 2010-04-01 The Trustees Of Columbia University In The City Of New York Use of trpv1 receptor agonists in cervical pain and labor
US20120077888A1 (en) 2009-03-26 2012-03-29 Royal College Of Surgeons In Ireland Orodispersible tablets
US20100260825A1 (en) 2009-04-13 2010-10-14 Nair Madhavan G Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches
RU2394814C1 (ru) 2009-05-22 2010-07-20 Учреждение Российской академии наук Институт органической химии Уфимского научного центра РАН Средство, представляющее собой этиловый эфир (±)-11,15-дидезокси-16-метил-16-гидроксипростагландина e1, проявляющее утеротоническую активность
PL2579866T3 (pl) 2010-06-11 2017-01-31 Ferring B.V. Dopochwowe podawanie mizoprostolu
CN102302443B (zh) 2011-09-21 2014-04-23 天津市聚星康华医药科技有限公司 一种米索前列醇阴道缓释栓剂及其制备方法
CN102697746B (zh) * 2012-06-11 2014-03-19 广州朗圣药业有限公司 一种快速融变的米索前列醇阴道用组合物及其制备方法和应用
EP2689781A1 (en) 2012-07-26 2014-01-29 Ferring B.V. Misoprostol composition
CN104487077A (zh) 2012-07-26 2015-04-01 辉凌公司 米索前列醇制剂
KR20150038174A (ko) 2012-07-26 2015-04-08 훼링 비.브이. 미소프로스톨 조성물
EP2689802A1 (en) 2012-07-26 2014-01-29 Ferring B.V. Misoprostol formulation
CN102872024B (zh) * 2012-09-28 2015-06-17 天津市聚星康华医药科技有限公司 口腔内使用的米索前列醇药物组合物
CN103040842B (zh) 2012-12-08 2014-11-12 浙江圣博康药业有限公司 一种前列腺素类药物组合物及其制成的前列腺素类药物栓剂
CN103340837B (zh) * 2013-07-08 2018-04-27 天津市聚星康华医药科技有限公司 一种米索前列醇阴道泡腾片及其制备方法

Also Published As

Publication number Publication date
WO2016004960A2 (en) 2016-01-14
JP6532529B2 (ja) 2019-06-19
CA2954086A1 (en) 2016-01-14
AU2015287186A1 (en) 2017-01-19
JP2017520628A (ja) 2017-07-27
EP3166597A2 (en) 2017-05-17
WO2016004960A3 (en) 2016-03-17
RU2017104233A3 (enExample) 2018-12-18
NZ727876A (en) 2018-05-25
JP6921894B2 (ja) 2021-08-18
PL3166597T3 (pl) 2025-11-17
EA039069B1 (ru) 2021-11-30
MX392771B (es) 2025-03-24
FI3166597T3 (fi) 2025-09-16
DK3166597T3 (en) 2025-09-01
US12005041B2 (en) 2024-06-11
CA2954086C (en) 2020-03-31
AU2015287186B2 (en) 2018-05-31
RU2017104233A (ru) 2018-08-13
US20220347145A1 (en) 2022-11-03
MX2017000399A (es) 2017-08-10
US20210322356A1 (en) 2021-10-21
US11406615B2 (en) 2022-08-09
BR112017000529A2 (pt) 2017-11-14
EP3166597B1 (en) 2025-08-06
EA201692536A1 (ru) 2017-06-30
JP2019147831A (ja) 2019-09-05

Similar Documents

Publication Publication Date Title
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PL3515420T3 (pl) Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
TN2014000131A1 (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
IL260766B (en) Continuous production of complexes containing active pharmaceutical ingredients
MX373272B (es) Terapia de combinacion.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MX370436B (es) Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica.
MX362533B (es) Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
ZA201607245B (en) Maternal vitamin b2 administration for the prevention of increased adiposity, overweight or obesity in the offspring
MX392771B (es) Tableta dispersable de misoprostol.
SI3731817T1 (sl) Farmacevtski sestavek farmacevtsko sprejemljive adicijske soli lenalidomida s kislino
JO3321B1 (ar) قرص قابل للتشتت من ميزوبروستول
MX2016006742A (es) Composicion farmaceutica.
IL257689A (en) Pharmacological preparations and methods for the treatment of diseases associated with hypoxia
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency